MIOCA IN THE NEWS
Please see our news in the archive to the right.
MIOCA Reaches $500,000 in Research Grants Awarded in Michigan
May 7, 2019
ANN ARBOR, MI - On World Ovarian Cancer Day, the Michigan Ovarian Cancer Alliance (MIOCA) announces an important milestone in its effort to save lives. Since it started giving grants in 2014, MIOCA has now awarded over a half-million dollars to researchers in Michigan who are finding new ways to improve the early detection and treatment of ovarian cancer.
“MIOCA is pleased to announce three 2019 Geri Fournier Ovarian Cancer Research Award winners, who will each receive $50,000 as part of our efforts to forward ovarian cancer research in our state.” said MIOCA Founder and President, Pam Dahlmann. The Award, named for the Founders’ mother who helped establish MIOCA before her death from ovarian cancer in 2011, was created to recognize the critical research happening right here, in our state, which is often underfunded. “Each and every research project we fund has the potential to result in improved understanding of the disease that will hopefully transform lives for women across Michigan and beyond.”
The State of Michigan is fortunate to have several of the nations’ top ovarian cancer researchers, and this year’s winners represent three institutions who are leading the way in ovarian cancer research. This year’s winners are:
• Rebecca Liu, M.D, Saint Joseph Mercy Health System,
University of Michigan Rogel Cancer Center
Michigan Cancer Research Consortium
"EASE: Education, Alliance, Solace, and Empowerment for
Ovarian Cancer Patients."
• Nouri Neamati, Ph.D., University of Michigan College of Pharmacy, and
Karen McLean, M.D., Ph.D., University of Michigan Medical School,
University of Michigan Rogel Cancer Center
"Development of STAT3 inhibitors for the treatment of ovarian cancer."
• John Risinger, Ph.D., Michigan State University
College of Human Medicine
"PARP inhibition and non-BRCA DNA damage repair mutation."
For the entire Press Release, click here.
MSU - Kelli Hughes 5K
April 27, 2019
MIOCA would like to sincerely thank Maria Tomovski and her team of students from Michigan State University for hosting the Kelli Hughes 5K this year! The weather was cold but the reason we were all there kept us warm. Go Green!
April 2, 2019
MIOCA often gets news about Clinical Trials. The trials below are in progress and are looking for participants. As a matter of policy, MIOCA does not endorse or recommend any treatment or study. You should always consult with your gynecologic oncologist before starting a clinical trial. Click on the study name for more information.
ATHENA – Rucaparib and Novolumab for Maintenance in Ovarian Cancer
ATHENA is a study for women who are newly diagnosed with ovarian cancer. ATHENA is looking at whether maintenance therapy with a PARP inhibitor and/or immunotherapy improves outcomes for women who have completed front-line ovarian cancer treatment.
GEM – Genetic Education for Men Study
The Genetic Education for Men study is a clinical trial evaluating educational tools for men from families in which a BRCA1/2 gene mutation has been identified. In order to identify untested men from BRCA1/2 families, we are seeking women who received positive BRCA1/2 test results and have at least one untested male relative.
ARIEL4 - Rucaparib and Recurrent Ovarian Cancer
ARIEL4 is a treatment study for women with relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a BRCA1 or BRCA2 mutation. ARIEL4 is designed to evaluate rucaparib against standard of care chemotherapy in women who have had at least two prior chemotherapy regimens. Visit the ARIEL4 Study page for more information.
WISP - Women Choosing Surgical Prevention
This study is open to pre-menopausal women between 30-50 with a mutation in BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, BARD1, MSH2, MSH6, MLH1, PMS2 or EPCAM. Women choose to either have their fallopian tubes removed now and their ovaries later or to have their tubes and ovaries removed at the same time. Outcomes are sexual function and quality of life between the women grouped by surgical procedure.
MAGENTA - MAking GENetic Testing Accessible
The MAGENTA study is open to women 30 years of age or older who may be at increased risk to develop ovarian cancer based on their personal or family history. Participants who qualify for this study will undergo genetic testing (using a saliva sample) for 19 genes associated with inherited cancer risk (including BRCA1 and BRCA2), and complete a series of online questionnaires regarding their experience. Some individuals in this study will undergo genetic counseling over the phone; others will not. Participation in this trial will not require any travel, but will require access to the internet and phone.
National Ovarian Cancer Advocacy Day in Washington, D.C.
March 5, 2019
Earlier this month, a delegation of 10 MIOCA representatives traveled to Washington, D.C. to join almost 100 advocates in the National Ovarian Cancer Advocacy Day, coordinated by our national partners at the Ovarian Cancer Research Alliance. The MIOCA team included six ovarian cancer survivors and two caregivers, five of whom received a MIOCA Advocacy scholarship to support their participation! Following a day of advocacy training, our team visited our two Michigan Senators and eight of our Representatives to advocate for increased funding for ovarian cancer research and education, including:
- $6.5 billion for the National Cancer Institute
- $9.5 million for the Ovarian Cancer Control Initiative at the CDC
- $12 million for Johanna’s Law at the CDC
- $35 million for the Ovarian Cancer Research Program, housed within the Department of Defense
Overall, our team was very well received and felt significant support from our Congressional Representatives. Senators Debbie Stabenow and Gary Peters, who have been long-time allies, expressed their continued commitment to our efforts. Representative Elisa Slotkin, who spoke publicly during her recent campaign about her mother’s death from Ovarian Cancer, has already become a strong advocate, and has joined the Ovarian Cancer Caucus and signed a letter of support for our increased funding requests.
While these meetings were important, the follow up that happens throughout the year on both the national and state levels is equally important. For this reason, MIOCA has developed a new Advocacy Committee which will stay informed about pending legislation and help organize grassroots advocacy when needed. If you are interested in joining, please send an email through the “Contact Us” page and specify that you are interested in Advocacy.
MIOCA announces new Outreach and Event Coordinator - Lisa Swanson
February 7, 2019
Lisa joined MIOCA in February 2019 as the new Outreach & Event Coordinator. Lisa joins us with an extensive background in non-profit event management and fundraising including creating and managing her own non-profit charity, Chicks4Charities, for the past 11 years. As a graduate of Michigan State University, Lisa prides herself on being a lifelong advocate for women’s issues, health, and rights.
“I am extremely excited to join the MIOCA team. The passion and drive of this talented organization far surpasses anything I have witnessed. I am proud to be an integral part of making a true difference through the incredible work accomplished by MIOCA and this amazing team.”
~Lisa M. Swanson
MIOCA announces the 2019 Geri Fournier Ovarian Cancer Research Opportunity - Awards announced by March 31!
February 2, 2019
The Michigan Ovarian Cancer Alliance Board of Directors is proud to once again offer research grant opportunities for the upcoming grant cycle. Pam Dahlmann, MIOCA President, states, "It is critical that innovative research be funded if there are to be gains made in discovering improved treatments or an early detection test. It is very exciting that, with the generous support of our donors, we have been able to provide a total of $350,000 to researchers here in Michigan through the Michigan Ovarian Cancer Alliance Geri Fournier Ovarian Cancer Research Grant program since its inception in 2015."
MIOCA's Board would like to thank all of the researchers who applied for the Geri Fournier Ovarian Cancer Research Grant. Awards will be announced by March 31, 2018.
MIOCA welcomes new Executive Director
January 4, 2019
Amy Friedman Milanovich, MPH: Executive Director
Amy joined MIOCA in December 2018 as its Executive Director, charged with institutionalizing its activities and expanding its impact. As a longtime Program Director at the University of Michigan School of Public Health and more recently as the Executive Director of the nonprofit organization GrieveWell, Amy brings a wealth of knowledge and experience in nonprofit administration and strategic planning, program management, and development. With a special interest in women and children’s health, her past work experience includes managing national community-based research initiatives in pediatric asthma and obesity, infant mortality initiatives in New Orleans, and nonprofit organizations in Ann Arbor and Washington, D.C.
A message from our new Executive Director:
I am honored to be named MIOCA’s new Executive Director, joining a team of smart, strong, and passionate individuals fighting for women’s lives and well-being! I have been a fan and proud supporter of MIOCA for several years, and have been impressed by the amazing work its staff and volunteers have accomplished. I look forward to lending my time, energy, and expertise to work with the MIOCA community to increase its impact throughout our state! This is no small task and takes a wide-reaching team of people. If you are not already involved, we encourage you to consider it! We are always looking for folks who are interested in helping run educational programs, advocate for new laws and policies, and/or organize awareness and fundraising events. If you want more information please visit our website www.mioca.org and/or email us at firstname.lastname@example.org. Together we CAN make a difference!